March 30th 2025, 2:00pm
By Alex Biese
There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.
March 29th 2025, 2:00pm
By Dr. Regina Hampton
Dr. Regina Hampton discusses key factors contributing to this disparity, and how healthcare systems can address these challenges.
March 28th 2025, 9:11pm
By Ryan Scott
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.
March 28th 2025, 8:00pm
By Laura Yeager
I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.
March 28th 2025, 7:11pm
By Leslie Waltke
CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.
March 28th 2025, 5:13pm
By Spencer Feldman
FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.
March 28th 2025, 4:00pm
A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
March 28th 2025, 3:00pm
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.
March 28th 2025, 1:00pm
Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.
March 27th 2025, 9:00pm
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
March 27th 2025, 8:53pm
By Georgina Long
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
March 27th 2025, 7:00pm
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
March 27th 2025, 5:00pm
By Bonnie Annis
Cancer memories often sneak up on me when I least expect them to.
March 27th 2025, 4:00pm
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.
March 27th 2025, 3:00pm
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
The Characterization of GIST: What Patients Should Know
Back to School Time Creates ‘Perfect Storm’ For Families Facing Cancer
Is Resistance Training Safe for Patients With Breast Cancer?
What Patients With GIST Need to Know About Their Disease